Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Survivor Story

Patient Info: Daniel West, Male | Stage II

Biomarkers: EGFR alteration

At the latest report, Daniel had no evidence of active cancer; small lung nodules were being monitored without progression while he continued osimertinib.

Lung cancer treated with targeted therapy: rare blood vessel inflammation as a side effect

Patient Info: Anonymized, Female | Stage IV

Biomarkers: BRAF mutation

Metastatic Site: pleura

She initially achieved a complete response. After vasculitis treatment, targeted therapy continued and a partial lung-cancer response remained maintained without vasculitis recurrence.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Niko's Patient Story

Patient Info: Niko, Female | Stage IV

Biomarkers: ALK mutation/rearrangement

Metastatic Site: Lymph nodes; Brain

As of May 2024, Niko’s Stage IV ALK-positive lung adenocarcinoma was controlled on ALK-targeted therapy, with no brain lesion seen on follow-up MRI/PET-CT and active disease described as dormant/stable.

YouTube (ZH search)Read more →

MSI-High Metastatic Hormone-Receptor-Positive Breast Cancer Responding to Pembrolizumab

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; MSI-high; BRCA mutation-negative

Metastatic Site: bone, para-aortic lymph nodes, brain

Pembrolizumab produced marked improvement in metastatic bone and nodal disease. After 1 year it was stopped because of appetite loss; 8 months later she was symptom-free and back at work on endocrine therapy, although asymptomatic brain metastases were documented.

PubMed CentralRead more →

Triple-negative breast cancer and ovarian cancer treated with chemotherapy and PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Germline pathogenic BRCA2 c.6468_6469del; breast tumor triple-negative

As of April 2024, 6-week follow-up after breast and nodal radiation was unremarkable, erythema had resolved, and no breast, chest wall, respiratory, or axillary abnormality was found; longer-term control was not reported.

PubMed CentralRead more →

Stage 4 lobular breast cancer: bone therapy switch to denosumab

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Not reported for breast cancer; CRP 21 mg/dL and ESR 27 mm/hr were elevated during orbital inflammation workup

Metastatic Site: bone

As of April 2024, zoledronate-associated ocular inflammation resolved within 2.5 weeks, vision returned to 20/20 after about 3 weeks, and bone-support treatment was changed to denosumab; breast-cancer response was not reported.

PubMed CentralRead more →

ALK-positive lung adenocarcinoma complicated by crizotinib-associated kidney and liver cysts

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: ALK fusion

Metastatic Site: bone

After switching from crizotinib to alectinib, the lung cancer and hilar lymph nodes remained stable at the latest follow-up described.

PubMed CentralRead more →

Jeff

Patient Info: Jeff, Male | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain|bones|lymph nodes

The lung mass shrank, 5 brain lesions and the involved lymph node had no evidence of disease, and Jeff described his condition as stable while continuing osimertinib and bone-strengthening infusions.

Lung Cancer Research FoundationRead more →

HER2-positive apocrine breast cancer: chemotherapy and Herceptin

Patient Info: Anonymized, Female, 60s

Biomarkers: HER2-positive; AR-positive; ER-negative; PR-negative

Disease-free for 2 years after treatment for HER2-positive apocrine breast cancer, with no reported lymph-node recurrence or distant metastases during surveillance.

PubMed CentralRead more →

Elsa Lankford

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Biomarker testing completed; results not reported

She remained in treatment for Stage IV colon cancer and had entered immunotherapy trial NCT05572684; reported side effects included skin rashes and increased anxiety.

Fight Colorectal CancerRead more →

BRAF V600E lung adenocarcinoma with a response lasting more than 5 years on dabrafenib and trametinib

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: BRAF ; PD-L1 TPS 100%

Metastatic Site: pleura

More than 5 years after her initial presentation, dabrafenib plus trametinib remained effective with no trend toward tumor progression.

PubMed CentralRead more →

Stage IV BRAF-mutated lung adenocarcinoma responding to second-line chemo-immunotherapy

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: BRAF exon 15 p.T599dup; PD-L1 5%

Metastatic Site: pleura, pericardium

After progression on BRAF/MEK-targeted therapy, second-line chemo-immunotherapy produced a partial response that was still ongoing after about 1 year of second-line treatment.

PubMed CentralRead more →

Ovarian Cancer Spreads to the Breast During Platinum-Resistant Recurrence

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1/2-negative; HRD-positive; PD-L1-positive; folate receptor alpha-positive

Metastatic Site: right breast, right axillary lymph nodes, cervical…

She remained alive with stable disease about 2 years after the breast metastasis was diagnosed while receiving seventh-line mirvetuximab-soravtansine.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient StoryRead more →

HER2-Positive Metastatic Breast Cancer With Recurrent Severe Hypocalcemia - Case 2

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: bone, liver

She died about 7 years after her breast-cancer diagnosis after rapid deterioration from liver metastases.

PubMed CentralRead more →

ALK-positive lung cancer treated with alectinib throughout pregnancy

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ALK rearrangement / fusion-positive

Metastatic Site: pleura; liver; bone; brain

Alectinib produced a complete radiologic response and maintained intracranial control through pregnancy. She delivered a healthy infant at 37 weeks, with normal development at 26 months.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Anne's Patient Story

Patient Info: Anne Laporte, Female | Stage IV

Biomarkers: EGFR-mutated; several additional mutations mentioned but not specified

Metastatic Site: Spine; liver; lymph nodes

As of March 2024, Anne was living with Stage IVB EGFR-mutated NSCLC on a clinical trial after progression on Tagrisso, with early signs of decreased tumor burden and major improvement in pain.

The Patient StoryRead more →

EGFR L858R/S768I lung adenocarcinoma with more than 5 years of survival after targeted therapy

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R and S768I compound mutation

Metastatic Site: bone, brain

He died on August 15, 2022, about 5 years and 4 months after his April 2017 presentation; afatinib had provided more than 3 years of disease control before later bone and brain progression.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR T790M mutation

Metastatic Site: Both lungs / bilateral lung nodules

As of March 2024, Ashley was living with Stage IV EGFR-mutated NSCLC controlled on daily Tagrisso for 43 months, with stable scans but no cancer-free or NED claim.

The Patient StoryRead more →

Stage IV ALK Lung Adenocarcinoma: Keegan's Survivor Story

Patient Info: Keegan Murphy, Male, 40s | Stage IV

Biomarkers: ALK fusion mutation

Metastatic Site: Lungs; lymph nodes; ribs/bone; abdomen

As of March 2024, Keegan had gone from Stage IV ALK-positive lung adenocarcinoma with tumors in the lungs, lymph nodes, ribs, and abdomen to no evidence of disease after alectinib and surgery.

MD AndersonRead more →

Stage IV lung adenocarcinoma presenting as a painful thigh metastasis

Patient Info: Anonymized, female, 40s | Stage IV

Metastatic Site: right thigh soft tissue/muscle, bilateral iliac bones…

After 9 months of therapy, the lung lesion had a partial response and the painful thigh mass had markedly decreased, although she remained unable to walk.

PubMed CentralRead more →

ALK-positive Stage IV lung adenocarcinoma controlled with alectinib despite hemolytic anemia

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: ALK-positive

At 1 year after starting alectinib, the tumor had not regrown and treatment was continuing intermittently despite persistent mild anemia.

PubMed CentralRead more →

Left Breast Cancer in a BRCA2 Carrier Treated With Mastectomy, Chemotherapy, and an Arm Port

Patient Info: Anonymized, female, Under 40

Biomarkers: Hormone receptor-positive; HER2-negative; pathogenic BRCA2 variant

At 17 months after surgery, she was free from disease and reported good quality of life and satisfaction with reconstruction and the arm port.

PubMed CentralRead more →

BRCA1-Mutated Ovarian Cancer Responding to Niraparib After Olaparib Progression

Patient Info: Anonymized, Female, 60s

Biomarkers: Germline BRCA1 pathogenic variant c.188T>A; CA-125 4

Two months after starting niraparib, imaging showed a partial response and CA-125 normalized. At 15 months, she had achieved a complete response and remained progression-free while niraparib continued.

PubMed CentralRead more →